US And Europe Hepatic Veno Occlusive Disease Treatment Market: By Drug Class (Heparin, Tissue Plasminogen Activators (t-PA), Antithrombin III (ATIII) Replacement, Defibrotide, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online pharmacies) and Country  

Purchase Option

$ 3100
$ 4600
$ 8900

The hepatic venous-occlusive disease also known as Sinusoidal Obstruction Syndrome (SOS) is characterized by obstruction of small veins in the liver. In this condition, the blood gets blocked in the small veins, due to the blockage of blood in small veins, blood is congested in the liver which leads to a reduction of blood flow into the liver and damages the hepatic cells. Due to the congestion, the liver gets enlarged and finally causes liver cirrhosis. Hepatic veno-occlusive disease caused due to the long-term use of certain drugs, which can cause serious effects on the liver and during bone marrow and stem cell transplantation. There is no specific treatment for the veno-occlusive disease, however, it can be treated by normalizing the blood flow in hepatic blood vessels by controlling fibrin deposition and vasculitis.   Europe's Hepatic Veno Occlusive Disease Treatment Market is in a nascent stage, as very few drugs are available for the treatment. Healthcare professionals are majorly focussing on alternative treatments to normalize the blood flow in hepatic small veins. Currently, market players are focusing on the development of new drugs for the treatment of hepatic veno-occlusive disease. Acquisitions and mergers, collaborations, and product launches are the key strategies followed by companies to increase their revenue share in the hepatic veno-occlusive treatment market. For instance, in July 2014, Jazz Pharmaceuticals, Plc. inked an agreement with Sigma-Tau Pharmaceuticals, Inc. to acquire rights to Defibrotide in the U.S. and all other countries of the Americas. 

US And Europe Hepatic Veno Occlusive Disease Treatment Market Key Developments:
  • In March 2016, Jaz Pharmaceuticals Plc. received FDA approval for Defitelio used in the treatment of hepatic veno-occlusive disease treatment

Us Europe Hepatic Veno Occlusive Disease Treatment Market Dynamics

An increase in the prevalence of cancer diseases that require chemotherapy and radiotherapy, a rise in the adoption of bone marrow and stem cell transplantation, excessive consumption of alcohol, obesity, and a rise in the prevalence of viral hepatitis are anticipated to fuel the hepatic veno-occlusive disease market. Moreover, increases in R&D activities for the innovation of newer drugs, lifestyle changes, and increases in healthcare expenditure are boosting the hepatic-veno occlusive disease treatment market. However, lack of specific treatment options, a high cost of treatment, and stringent regulations and guidelines for drug approval might hinder the growth of the U.S. And Europe's Hepatic Veno Occlusive Disease Treatment Market.

Us Europe Hepatic Veno Occlusive Disease Treatment Market Segmentation

By Drug Class
  • Heparin
  • Tissue Plasminogen Activators (t-PA)
  • Antithrombin III (ATIII) Replacement
  • Defibrotide
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online pharmacies

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Jazz Pharmaceuticals Plc. (Ireland)
  • Novartis AG (Switzerland)
  • Norgine Pharmaceuticals Ltd. (U.K.)

Adjacent Markets